Replication, pathogenicity, and transmission of SARS-CoV-2 in minks

Lei Shuai¹,²,†, Gongxun Zhong¹,²,†, Quan Yuan³,†, Zhiyuan Wen¹,²,†, Chong Wang¹,†, Xijun He¹,²,†, Renqiang Liu¹,², Jinliang Wang¹,², Qinjian Zhao³, Yuxiu Liu⁴, Ningning Huo⁴, Junhua Deng⁴, Jingjing Bai⁴, Hongchao Wu⁴, Yuntao Guan², Jianzhong Shi¹, Kegong Tian¹, Ningshao Xia⁴,³, Hualan Chen¹,*, and Zhigao Bu⁰¹,²,†

ABSTRACT

Minks are raised in many countries and have transmitted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to humans. However, the biologic properties of SARS-CoV-2 in minks are largely unknown. Here, we investigated and found that SARS-CoV-2 replicates efficiently in both the upper and lower respiratory tracts, and transmits efficiently in minks via respiratory droplets; pulmonary lesions caused by SARS-CoV-2 in minks are similar to those seen in humans with COVID-19. We further found that a spike protein-based subunit vaccine largely prevented SARS-CoV-2 replication and lung damage caused by SARS-CoV-2 infection in minks. Our study indicates that minks are a useful animal model for evaluating the efficacy of drugs or vaccines against COVID-19 and that vaccination is a potential strategy to prevent minks from transmitting SARS-CoV-2.

Keywords: SARS-CoV-2, mink, replication, pathogenicity, transmission, animal model

INTRODUCTION

Coronaviruses (CoV) have caused three epidemics in the 21st century, including severe acute respiratory syndrome (SARS) in 2003 [1], Middle East respiratory syndrome (MERS) in 2012 [2] and the currently spreading COVID-19 [3,4]. The causative pathogens for these three epidemics are SARS-CoV, MERS-CoV and SARS-CoV-2, respectively. Unlike SARS-CoV and MERS-CoV, which each caused human infections over a limited geographic area, SARS-CoV-2 has caused a pandemic [5–7]. As of 11 October 2020, over 37 million human cases have been reported, and more than one million humans have died from the infection [8].

SARS-CoV-2 shares the highest homology at the nucleotide level with the coronavirus RaTG13, which was found in horseshoe bats (Rhinolophus spp.) in Yunnan province, China, in 2013 [9], implying that the SARS-CoV-2 and RaTG13 may have descended from a similar ancestor. Although it remains unknown which animal(s) served as intermediate hosts to transfer the virus from its original host to humans, it has been reported that multiple animal species, including ferrets, hamsters, non-human primates, cats, dogs, tigers, raccoon dogs and minks are permissive for SARS-CoV-2 infection or have tested positive in the field [10–23]. Among these susceptible animals, minks are the only species farmed on a large scale in many countries that have transmitted SARS-CoV-2 to humans, suggesting their potential to become a new reservoir of SARS-CoV-2 [20,24]. However, the biologic properties of SARS-CoV-2 in minks are largely unknown. Here, we performed a detailed study to understand the replication, pathogenicity and transmission of SARS-CoV-2 in minks. We also explored the potential of minks to serve as model animals for the development of COVID-19 control measures.
Figure 1. Replication of SARS-CoV-2 in minks. Three minks were inoculated with HRB25 virus, and their nasal washes, concha swabs and rectal swabs were collected on days 2 and 4 post-infection (p.i.); organs were collected on day 4 p.i. for viral RNA detection and virus titration. (A) Viral RNA and (B) virus titers of nasal washes, concha swabs and rectal swabs of minks on days 2 and 4 p.i. (C) Viral RNA and (D) virus titers of organs of minks on day 4 p.i. ‘Others’ represents viral-negative organs, including the heart, kidneys, spleen, liver, pancreas and brain. Each color bar represents the value from an individual animal. The dashed lines indicate the lower limit of detection.

RESULTS

All experiments with infectious SARS-CoV-2 were performed in the biosafety level four and animal biosafety level four facilities in the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS), which were approved for such use by the Ministry of Agriculture and Rural Affairs of China. Details of the biosafety and biosecurity measures taken were described previously [14]. The protocols for animal study and animal welfare were reviewed and approved by the Committee on the Ethics of Animal Experiments of the HVRI of CAAS (approval number 2020-04-01JiPi).

SARS-CoV-2 replicates efficiently in the upper and lower respiratory tracts of minks

To investigate the replication and tissue tropism of SARS-CoV-2 in minks, three 13-month-old minks were inoculated intranasally (i.n.) with $5 \times 10^5$ plaque-forming units (PFU) in 1 mL of the SARS-CoV-2 HRB25 strain, which was isolated from a patient in Harbin in February 2020 [25]. Nasal washes, concha swabs and rectal swabs were collected on days 2 and 4 post-inoculation (p.i.) for viral RNA and infectious virus detection. On day 4 p.i., the minks were euthanized and their nasal turbinates, soft palates, tonsils, tracheas, lungs, hearts, submaxillary lymph nodes, kidneys, spleens, livers, small intestines and brains were collected for viral RNA and infectious virus detection.

Viral RNA was detected in the nasal washes of all three animals on days 2 and 4 p.i., and also from the ear swabs and rectal swabs of two animals on day 2 p.i. (Fig. 1A). Infectious virus was detected in the nasal washes of all three animals on days 2 and 4 p.i., but not from the concha swabs or rectal swabs of any animals at any time points (Fig. 1B). Viral RNA was detected in the nasal turbinates, soft palates, tonsils, all lung lobes and submaxillary lymph nodes of all three minks, in the trachea of two minks, and in the ileum of one mink, but was not detected in any other organs of any animal tested (Fig. 1C). Infectious virus was detected in most of the viral RNA-positive samples (Fig. 1D). These results demonstrate that SARS-CoV-2 can replicate efficiently in the upper and lower respiratory tracts of minks.

SARS-CoV-2 causes severe pathological injury in the respiratory tracts of minks

Nasal turbinate and lung samples of the minks that were euthanized on day 4 p.i. were also collected for pathological studies. Compared to the clean nasal cavity of the naïve control mink (Supplementary Fig. S1A), the nasal cavities of the virus-inoculated minks were filled with mucinous-purulent secretion, which was composed of neutrophil debris and mucus (Supplementary Fig. S1B and C). Inflammatory infiltrates, epithelial degeneration and necrosis were observed in the nasal mucosa and submucosa of the vestibular region (Supplementary Fig. S1D), respiratory region (Supplementary Fig. S1E) and olfactory region (Supplementary Fig. S1F). In the nasal mucinous-purulent secretion of the infected animals, numerous positive signals indicating SARS-CoV-2 nucleoprotein antigen (Supplementary Fig. S1H) were noted. Positive signals were also detected in the epithelium of the nasal mucosa of the
Figure 2. Histopathologic, immunohistochemical and histochemical studies. (A) Lung from control mink shows normal structure. (B-T) Lungs of minks infected with SARS-CoV-2. (B) Extensive and diffuse consolidation at sub-gross level. (C) Fibrinous necrosis of blood vessel wall (cinquefoil). (D) Intra-alveolar serous and fibrin exudation (asterisk). (E) Intra- and inter-alveolar hemorrhages (cloverleaf) and serous-fibrin exudation (asterisk). (F) Multinucleated syncytial cell in alveolar space (arrow). (G) Intra- and inter-alveolar foamy macrophage proliferation (arrow). (H) Severe lymphoplasmacytic perivasculitis and vasculitis (dotted line), and fibrin formation (asterisk) in a blood vessel. (I) Eosinophilic intranuclear inclusion body formation in a monocyte-like cell (□). (J) Degeneration of bronchiolar epithelium (arrow). (K) Peribronchiolar inflammatory infiltrate (dotted line). (L) Degeneration of bronchial gland epithelium. (M, N) Viral antigen-positive cells in the lung (arrow) and in (O) bronchi epithelium (arrow). (P) Marked proliferation of macrophages, monocytes and neutrophils, confirmed by immunohistochemistry with an anti-MAC387 antibody (arrow). (Q) Deposition of intra- and inter-alveolar collagen confirmed by Masson trichrome (blue) staining. (R) Embolus of mucous-fibrin mixture in bronchial lumen confirmed by Martius Scarlet Blue (MSB) staining (arrow). (S) Fibrin formation in a blood vessel confirmed by MSB staining (arrow). (T) Formation of microvascular thrombi confirmed by MSB staining (arrow). Scale bar in A, C, D, K, M and O = 200 μm; in E, G, H, J, L, N, P, Q, S and T = 100 μm; in F and I = 20 μm; and in R = 500 μm.

vestibular region, respiratory region and olfactory region (Supplementary Fig. S1I–K) and that of the tracheal mucosa (Supplementary Fig. S1L). These data suggest a major role for nasal secretion in transmission and olfactory function impairment, as has been reported in SARS-CoV-2-infected human patients [26].

The lungs of the virus-infected minks showed severe lesions with extensive and diffuse consolidation (Fig. 2B). At higher magnification, various histopathological changes were observed, including fibrinous necrosis of the blood vessels (Fig. 2C), intra-alveolar serous and fibrin exudation (Fig. 2D and E), hemorrhage (Fig. 2E), focal multinucleated syncytial cells (Fig. 2F), intra-alveolar and interalveolar septa proliferation and infiltration of macrophages (Fig. 2G), severe lymphoplasmacytic perivasculitis and vasculitis, and fibrin formation in blood vessels (Fig. 2H and I). A few instances of intranuclear inclusion bodies in monocyte-like cells (Fig. 2I), degeneration of bronchiolar epithelium (Fig. 2J), peribronchiolar inflammatory infiltrates (Fig. 2J and K) and degeneration of bronchial gland epithelium (Fig. 2L) were also noted. Viral
Table 1. Pathological characteristics observed in the lungs of minks infected with SARS-CoV-2 HRB25 strain.

| Lesions observed in minks                                      | Percentage of 129 COVID-19 human patients having the lesions on autopsy as reported by Polak et al. [27] |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Epithelial                                                   |                                                                                   |
| Diffuse alveolar damage                                      | 75%                                                                               |
| Desquamation and/or reactive hyperplasia of pneumocytes       | 72%                                                                               |
| Multinucleated giant cells                                   | 20%                                                                               |
| Viral inclusion bodies                                       | 20%                                                                               |
| Vascular                                                     |                                                                                   |
| Capillary congestion                                         | 45%                                                                               |
| (Micro) thrombi                                              | 39%                                                                               |
| Alveolar hemorrhage                                          | 33%                                                                               |
| Intra-alveolar fibrinous exudates                            | 26%                                                                               |
| Peri- or intravascular inflammatory infiltrites               | 9%                                                                                |
| Interstitial fibrous changes, septal collagen deposition      | 33%                                                                               |
| Other                                                        |                                                                                   |
| Interstitial and intra-alveolar inflammatory infiltrates      | 64%                                                                               |
| Intra-alveolar edema                                         | 46%                                                                               |

antigen-positive cells were detected in the bronchi and lungs of all animals on day 4 p.i. (Fig. 2M–O). There was marked proliferation of macrophages, monocytes and neutrophils in the lungs, which was confirmed by immunohistochemical staining with an anti-MAC387 antibody (Fig. 2P). Robust deposition of intra- and inter-alveolar mature collagen fibers was detected (Fig. 2Q); mucous-fibrin mixture deposits were detected in the bronchial lumen (red staining, Fig. 2R) and in the blood vessels (Fig. 2S and T). Importantly, most of these pathologic changes have been observed in human COVID-19 patients [27–29], as summarized in Table 1, suggesting that SARS-CoV-2 causes similar damage to the respiratory systems of minks and humans.

SARS-CoV-2 easily transmits among minks via respiratory droplets

To investigate the ability of SARS-CoV-2 to transmit among minks via respiratory drops, three animals were inoculated i.n. with $5 \times 10^6$ PFU of HRB25 and each animal was placed in a separate cage within an isolator. Twenty-four hours later, three naive minks were placed in each cage adjacent to the ones that held the virus-inoculated mink without direct contact. Nasal washes, and rectal and concha swabs were collected every other day from day 2 to 18 p.i. from the inoculated animals [and from day 1 to 17 post-exposure (p.e.) from the exposed animals] for viral RNA detection and virus titration. Body weights of all six animals were recorded every other day. In the three virus-inoculated minks, viral RNA was detected in the nasal washes of all three animals on days 2, 4, 6 and 8 p.i., and in the nasal washes of two animals and one animal on days 10 and 12 p.i., respectively, but not from any animals on days 14, 16 and 18 p.i. (Fig. 3A). Viral RNA was also detected in the concha swab of one mink on days 4 and 6 p.i. and in the rectal swab of another mink on day 8 p.i. (Supplementary Fig. S2A). Among the exposed minks, viral RNA started to be detected in the nasal washes of one, two and all three animals on days 3, 5 and 9 p.e., respectively (Fig. 3A). Viral RNA was also detected from the concha swab and rectal swab of one mink on day 11 p.i. and day 13 p.i., respectively (Supplementary Fig. S2A and C). Infectious virus was detected in the nasal washes of the infected minks from days 2 to 8 p.i., and in the nasal washes of the exposed animals from days 5 to 11 p.e. (Fig. 3B), but was not detected in the concha swabs or rectal swabs of any of the minks (Supplementary Fig. S2B and D). The inoculated minks experienced 10%–20% body weight loss during the 18-day observation period (Fig. 3C); one virus-inoculated mink experienced watery nasal discharge. The exposed minks lost about 5% of their body weight (Fig. 3D). All of the inoculated and exposed minks seroconverted on day 18 p.i. (Fig. 3E and F). These data indicate that SARS-CoV-2 easily transmits among minks via respiratory droplets.

A spike protein-based subunit vaccine protects minks against SARS-CoV-2

The above studies indicate that minks are most similar to humans in terms of replication, transmission and lung lesions after being infected with SARS-CoV-2, making minks a potential animal model for SARS-CoV-2 study and COVID-19 control measure evaluation. In addition, since minks are raised in many countries, actions are urgently needed to prevent farmed minks from becoming a reservoir of SARS-CoV-2. We therefore evaluated the protective
efficacy of a spike protein-based subunit vaccine against SARS-CoV-2 in minks. Six 13-month-old minks were immunized intramuscularly with two doses of an aluminium-adjuvanted subunit vaccine; each dose contained 25 μg of the spike protein in a 0.5-mL volume, and there was a two-week interval between immunizations. Sera were collected at different time points from the vaccinated minks for detecting antibodies against SARS-CoV-2. The animals were challenged intranasally with $5 \times 10^6$ PFU of HRB25 at five weeks post the second dose vaccine inoculation.

One and four of the six vaccinated minks developed antibodies to SARS-CoV-2 one week and two weeks after the first vaccination, respectively, and all of the six minks developed antibodies against SARS-CoV-2 after the second dose vaccination tested by an enzyme linked immunosorbent assay (ELISA) (Supplementary Fig. S3A). At five weeks after the second immunization, the neutralization antibody titers of the minks ranged from 64 to 256 ($6\log_2$ to $8\log_2$) (Supplementary Fig. S3B). Three vaccinated minks and three control minks were euthanized on day 4 post-challenge (p.c.). Among the three vaccinated animals, viral RNA of the challenged virus was detected in the nasal turbinate, soft palate and tonsil of one or two of the three animals, and in one lung lobe of one mink (Fig. 4A), but infectious virus was not detected in any organs tested (Fig. 4B). In contrast, high copy numbers of viral RNA and infectious virus were detected in all of the tested organs of the control minks, except for the tonsils, in which infectious virus was not detected (Fig. 4A and B). Histological studies of lung samples from the vaccinated minks revealed mild perivasculitis with/without slight peribronchiolitis and interstitial pneumonitis (Supplementary Fig. S4A–C), but viral antigen was not detected in the lungs of any of the minks (Supplementary Fig. S4D–F). Lung samples from the control minks showed acute interstitial pneumonia, severe perivasculitis and moderate peribronchiolitis (Supplementary Fig. S4G–I); the lung parenchyma contained a large amount of diffuse viral antigen (Supplementary Fig. S4J–L).

Nasal washes of the three remaining minks in each group were collected for viral RNA detection and infectious virus titration. Viral RNA was detected in the nasal washes of the control minks on days 2, 4, 6, 8, 10 and 12 p.c., but was only detected in the nasal washes of the vaccinated minks on days 2, 4 and 6 p.c. with significantly low levels (Fig. 4C). Infectious virus was detected in the nasal washes of the control minks on days 2, 4, 6 and 8 p.c., but was only detected in the nasal wash of one vaccinated mink on day 2 p.c. (Fig. 4D). These studies show that the spike protein-based subunit vaccine largely prevented the replication of SARS-CoV-2 in the upper and lower respiratory tracts of the minks, and prevented SARS-CoV-2-induced lung damage in minks.
Figure 4. Protective efficacy of a spike-based subunit vaccine against SARS-CoV-2 challenge in minks. Six vaccinated or control minks were challenged with SARS-CoV-2 HRB25. Three minks from each group were euthanized on day 4 post-challenge (p.c.) and their organs were collected for viral RNA detection (A) and infectious virus titration (B); nasal washes of the three other remaining minks in each group were collected for viral RNA detection (C) and infectious virus titration (D). The horizontal dashed lines indicate the lower limit of detection. Viral RNA and viral titers of control and vaccinated minks were statistically analyzed by using the one-tailed unpaired t-test. Single asterisk indicates $P < 0.05$, and double asterisks indicate $P < 0.01$.

DISCUSSION

In summary, we performed detailed studies to investigate the replication, transmission and pathogenicity of SARS-CoV-2 in minks and found that SARS-CoV-2 replicates efficiently in both the upper and lower respiratory tracts and causes severe lesions in the nasal mucosa and lungs of minks. In addition, we found that SARS-CoV-2 transmits efficiently in minks via respiratory droplets. Oreshkova et al. reported that SARS-CoV-2 was lethal in farmed pregnant minks [20]; however, in the present study, we found that virus-inoculated minks lost 10%–20% of their body weight at around day 8 p.i., and exposed minks lost about 5% of their body weight, but none of the virus-inoculated or exposed minks died. The exposed animals lost less body weight than the virus-inoculated animals, largely because the initial dose received by the exposed animals was much lower than that received by the inoculated animals, although the titer of the virus in the exposed animals reached a peak level similar to that of the inoculated animals. These findings suggest that pregnant minks may be more vulnerable to SARS-CoV-2 infection than non-pregnant ones. Given that minks are highly susceptible to SARS-CoV-2 and could be easily infected by this widely spreading virus, surveillance and active control measures in minks should be implemented to prevent minks from becoming reservoirs of SARS-CoV-2.

Animal models are needed for the evaluation of vaccines and antiviral drugs for COVID-19. Human angiotensin-converting enzyme 2 (hACE-2) receptor transgenic mice have been generated and proved to be susceptible to SARS-CoV-2 infection, resulting in a range of clinical signs with mild to fatal disease depending on the transgene [30–33]. SARS-CoV-2 adaptation to mice has also been attempted through either serial passaging or reverse genetics [34–36]. Non-human primates, including rhesus macaques, African green monkeys and marmosets, have been shown to be susceptible to SARS-CoV-2 infection [37–40]. Ferrets have also been shown to be susceptible to SARS-CoV-2 infection resulting in mild disease with shedding from the upper respiratory tract [14,17,41,42]. Both minks and ferrets are mustelid and are highly susceptible to SARS-CoV-2; however, the replication patterns of SARS-CoV-2 in ferrets and minks are different. Studies show that the host factors, such as ACE2 [9,43–45] and neuropilin-1 [46,47], play important roles in SARS-CoV-2 replication; it remains to be investigated if ferrets and minks have different expression levels of these critical host factors in their organs. SARS-CoV-2 efficiently replicates in the upper respiratory tract of ferrets, but its replication in the lungs of ferrets is undetectable [14]. Therefore, the ferret model can only be used to assess the efficacy of vaccines or antivirals in preventing or reducing virus replication in the upper respiratory tract; it cannot be used to evaluate whether they reduce or eliminate lung lesions. SARS-CoV-2 replicates in the upper and lower respiratory tracts of minks and causes lung lesions...
highly similar to those seen in human COVID-19 patients [27,29]. Accordingly, using minks as model animals will enable us to more precisely evaluate the efficacy of antiviral drugs or vaccines for COVID-19.

Minks are raised on a large scale in many countries and are at high risk of SARS-CoV-2 infection. In fact, SARS-CoV-2 infection of minks has been reported in several countries in Europe and the Americas, and millions of minks have been culled to control the spread of the virus [24]. In the present study, we found that a spike protein-based subunit vaccine largely prevented SARS-CoV-2 replication and protected minks from SARS-CoV-2-induced lung damage. Our previous studies with H7N9 influenza viruses have shown that vaccinated animals could be perfectly protected from exposure to virus infected animals, even though the vaccine cannot provide complete protection when the animals were challenged by direct infection [48,49]. Given that the vaccine provided sound protection to a high dose of SARS-CoV-2 challenge, it is reasonable to speculate that the vaccinated animals would be protected from infection of natural exposure. Vaccination may, therefore, be an option for preventing SARS-CoV-2 infection of minks.

MATERIALS AND METHODS
The detailed descriptions of materials and methods are available as supporting information at NSR online.

DATA AND MATERIALS AVAILABILITY
All data are available in the manuscript and the supplementary materials.

SUPPLEMENTARY DATA
Supplementary data are available at NSR online.

ACKNOWLEDGEMENTS
We thank S. Watson for editing the manuscript.

FINANCING
This work was supported by the National Key R&D Program of China (2018YFC1200601, 2020YFC0846500 and 2020YFC0841100) and the Applied Technology Research and Development Project of Heilongjiang Province, China (GA20C006).

AUTHOR CONTRIBUTIONS
L.S., G.Z., Q.Y., Z.W., C.W., X.H., R.L., J.W., Q.Z., Y.L., N.H., J.D., J.B., H.W. and Y.G. performed the experiments; K.T., N.X., H.C. and Z.B. designed the study and analyzed the data; H.C. and Z.B. wrote the manuscript.

Conflict of interest statement. None declared.

REFERENCES
1. Peiris JS, Lai ST and Poon LL et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319–25.
2. Zaki AM, van Boheemen S and Bestebroer TM et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814–20.
3. Chan JF, Yuan S and Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514–23.
4. Zhu N, Zhang D and Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–33.
5. Mahase E. Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ 2020; 368: m641.
6. Wu A, Peng Y and Huang B et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020; 27: 325–8.
7. Zhu Z, Lian X and Su X et al. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res 2020; 21: 224.
8. World Health Organization. Coronavirus disease (COVID-2019) situation report for 11 October 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9 (16 October 2020, date last accessed).
9. Zhou P, Yang XL and Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–3.
10. Wang L, Mitchell PK and Calle PP et al. Complete genome sequence of SARS-CoV-2 in a tiger from a U.S. zoological collection. Microbiol Resour Announc 2020; 9: e00468–20.
11. Munster VJ, Feldmann F and Williamson BN et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 2020; 585: 268–72.
12. Sit THC, Brackman CJ and Ip SM et al. Infection of dogs with SARS-CoV-2. Nature 2020; 586: 776–8.
13. Bosco-Lauth AM, Hartwig AE and Porter SM et al. Experimental infection of domestic dogs and cats with SARS-CoV-2: pathogenesis, transmission, and response to reexposure in cats. Proc Natl Acad Sci USA 2020; 117: 26382–8.
14. Shi J, Wen Z and Zhong G et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 2020; 368: 1016–20.
15. Yu P, Qi F and Xu Y et al. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med 2020; 3: 93–7.
16. Freuling CM, Breithaupt A and Müller T et al. Susceptibility of raccoon dogs for experimental SARS-CoV-2 infection. Emerg Infect Dis 2020; 26: 2982–5.
17. Kim YI, Kim SG and Kim SM et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 2020; 27: 704–9.
18. Chan JF, Zhang AJ and Yuan S et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020; 71: 2428–46.
19. Zhang Q, Zhang H and Gao G et al. A serological survey of SARS-CoV-2 in cat in Wuhan. Emerg Microbes Infect 2020; 9: 2013–9.
20. Oreshkova N, Molenaar RJ and Vrman S et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Euro Surveill 2020; 25: 2001005.
21. Halfmann PJ, Hatta M and Chiba S et al. Transmission of SARS-CoV-2 in domestic cats. N Engl J Med 2020; 383: 582–4.
22. Rockx B, Kuiken T and Herfst S et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 2020; 368: 1012–5.
23. Saillaux C, Dumarest M and Vanhormwegen J et al. First detection and genome sequencing of SARS-CoV-2 in an infected cat in France. Transbound Emerg Dis 2020; 67: 2324–8.
24. Enserink M. Coronavirus rips through Dutch mink farms, triggering culls. Science 2020; 368: 1169.
25. Wu S, Zhong G and Zhang J et al. A single dose of an adenosivirus vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 2020; 11: 4081.
26. Chung TW, Srithar S and Zhang AJ et al. Olfactory dysfunction in coronavirus disease 2019 patients: observational cohort study and systematic review. Open Forum Infect Dis 2020; 7: ofaa199.
27. Polak SB, Van Goor IC and Cohen D et al. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol 2020; 33: 2128–36.
28. Zhou B, Zhao W and Feng R et al. The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review. Pathog Dis 2020; 78: ftau026.
29. Wagner WL, Heilbach K and Fiedler MO et al. Microvascular changes in COVID-19. Radiol 2020; 60: 934–42.
30. Bao L, Deng W and Huang B et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020; 583: 830–3.
31. Sun J, Zhuang Z and Zheng J et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 2020; 182: 734–43.
32. Sun SH, Chen Q and Gu HJ et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 2020; 28: 124–33.
33. Rathnasighe R, Strohmeier S and Amanat F et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect 2020; 9: 2433–45.
34. Wang J, Shai L and Wang C et al. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell 2020; 11: 778–82.
35. Leist SR, Dinnen KH, III and Schaefer A et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 2020; 183: 1070–85.
36. Gu H, Chen Q and Yang G et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 2020; 369: 1603–7.
37. Deng W, Bao L and Liu J et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 2020; 369: 818–23.
38. Chandrashekar A, Liu J and Martinot AJ et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 2020; 369: 812–7.
39. Lu S, Zhao Y and Wu W et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther 2020; 5: 157.
40. Woolsey C, Borisevich V and Prasad AN et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol 2021; 22: 86–98.
41. Richard M, Kok A and de Meulder D et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun 2020; 11: 3496.
42. Schlottau K, Rissmann M and Graaf A et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe 2020; 1: e218–25.
43. Hoffmann M, Kleine-Weber H and Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–80.
44. Letko M, Marzi A and Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020; 5: 562–9.
45. Yan R, Zhang Y and Li Y et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444–8.
46. Daly JL, Simonetti B and Klein K et al. Neuruplin-1 is a host factor for SARS-CoV-2 infection. Science 2020; 370: 861–5.
47. Cantuti-Castelvetri L, Ojha R and Pedro LD et al. Neuruplin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 2020; 370: 856–60.
48. Yang W, Yin X and Guan L et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect 2020; 9: 2433–45.
49. Wang J, Shai L and Wang C et al. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell 2020; 11: 778–82.
50. Leist SR, Dinnen KH, III and Schaefer A et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 2020; 183: 1070–85.
51. Gu H, Chen Q and Yang G et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 2020; 369: 1603–7.
52. Deng W, Bao L and Liu J et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 2020; 369: 818–23.
53. Chandrashekar A, Liu J and Martinot AJ et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 2020; 369: 812–7.
54. Lu S, Zhao Y and Wu W et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther 2020; 5: 157.
55. Woolsey C, Borisevich V and Prasad AN et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol 2021; 22: 86–98.
56. Richard M, Kok A and de Meulder D et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun 2020; 11: 3496.
57. Schlottau K, Rissmann M and Graaf A et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe 2020; 1: e218–25.
58. Hoffmann M, Kleine-Weber H and Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–80.
59. Letko M, Marzi A and Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020; 5: 562–9.
60. Yan R, Zhang Y and Li Y et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444–8.